Allos gets NDA rolling for efaproxiral
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allos will complete rolling NDA for its radiation sensitizer efaproxiral (RSR13) by year-end. The final component includes clinical information supporting use of efaproxiral as an adjunct to radiation therapy for the treatment of brain metastases from breast cancer. Allos initiated the submission in August with non-clinical information, and submitted CMC data in September